DIGNITY trial for RCW Breast Cancer
Posted on: October 5, 2009 user submitted | Views: | Comment
Celsion Corporation (NASDAQ:CLSN) announced today initiation of a nationwide enrollment program in its pivotal Phase I/II DIGNITY clinical trial evaluating the use of ThermoDox® in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer. In early studies, conducted at Duke University Medical Center, investigators report that ThermoDox® has demonstrated significant promise in treating this highly aggressive disease. To view Multimedia News Release, go to http://www2.prnewswire.com/mnr/celsion/39944/
